For investors who have followed the volatile trajectory of the cannabis industry over the last half-decade, the term “MSO” is synonymous with both immense potential and significant capital erosion. MSOs, or Multi-State Operators, represent the backbone of the legal cannabis market in the United States. These companies operate cultivation, manufacturing, and retail dispensaries across multiple jurisdictions where cannabis has been legalized for medical or adult use. However, the market performance of these stocks has been a harrowing journey for shareholders. To understand what happened to MSO stock, one must look past the surface-level price action and examine the convergence of regulatory stagnation, capital constraints, and the broader macroeconomic environment.
The Mirage of the Green Rush
In the early years of state-level legalization, the narrative surrounding MSOs was driven by a sense of inevitability. Investors poured billions into companies like Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs, betting that federal legalization was just around the corner. This period was characterized by rapid expansion, aggressive mergers and acquisitions, and a “land grab” mentality.
The Capital-Intensive Growth Model
The MSO business model is uniquely expensive. Unlike tech startups that scale through software, MSOs must navigate the logistical nightmare of federal prohibition. Because cannabis remains a Schedule I controlled substance under the U.S. Controlled Substances Act, MSOs cannot transport product across state lines. This forces them to replicate their entire supply chain—cultivation, processing, and distribution—within every single state they enter. This redundant infrastructure creates massive capital expenditure requirements. When the cost of capital was low, these companies financed their growth through equity offerings and high-interest debt. When the economic tide turned, this structural leverage became an anchor.
Valuations Disconnected from Reality
During the peak of the cannabis frenzy, valuations were untethered from fundamental financial metrics. Investors were paying astronomical multiples for future revenue that assumed a seamless transition to federal legality and nationwide banking access. When that legislative catalyst failed to materialize, the market underwent a violent “valuation reset,” causing stock prices to plummet by 80% to 90% from their all-time highs.
Regulatory Headwinds and the 280E Tax Burden
The single most destructive force affecting MSO stock performance is Section 280E of the Internal Revenue Code. This tax provision prohibits businesses that “traffic” in Schedule I or II substances from deducting standard business expenses. For an MSO, this means they pay federal income tax on their gross profit rather than their net income.
Profitability Under Pressure
While many MSOs have managed to generate positive operational cash flow, their bottom lines are decimated by 280E. Because they cannot write off marketing, rent, administrative salaries, or interest expenses, their effective tax rates often soar well above 70% to 80%. This tax burden makes it nearly impossible for these companies to build the massive cash reserves necessary to weather market downturns or invest in meaningful R&D. Shareholders, initially willing to overlook these costs in favor of revenue growth, eventually demanded profitability, which the current tax structure actively inhibits.
The Failed Promise of Reform
The market’s repeated disappointment regarding legislative progress has played a major role in the stock price decline. From the SAFE Banking Act to rumors of full rescheduling, the legislative “carrot” has been dangled in front of investors for years. Each time a bill stalls in the Senate or a legislative session ends without movement, MSO stock suffers a sell-off. This “buy the rumor, sell the news” cycle—often ending in the absence of news—has eroded long-term investor confidence and institutional interest.
Macroeconomic Shifts and the Institutional Exodus
The broader economic environment since 2022 has been particularly unkind to high-beta, growth-oriented sectors like cannabis. The transition from a zero-interest-rate policy (ZIRP) environment to one of aggressive monetary tightening by the Federal Reserve fundamentally altered the risk-reward profile for MSO investors.
The Cost of Debt
As interest rates rose, the cost of servicing the debt that MSOs took on during their expansion phase skyrocketed. Companies that were once able to refinance or secure cheap credit found the capital markets effectively shut off. Institutional investors, such as large hedge funds and pension funds, are largely barred from investing in cannabis due to the federal illegality of the underlying asset. This leaves the sector dominated by retail traders, resulting in extreme volatility and thin trading volumes. Without the “smart money” to stabilize the stock, MSOs have been left to drift lower on low-conviction selling pressure.
The OTC Market Limitation
Most MSOs trade on the Canadian Securities Exchange (CSE) or over-the-counter (OTC) markets in the United States. They are prohibited from listing on major American exchanges like the New York Stock Exchange (NYSE) or the Nasdaq. This lack of access to major exchanges precludes inclusion in index funds and ETFs, which are the primary drivers of consistent market capital inflows. For the average investor, accessing these stocks often involves higher fees and less liquidity, further dampening interest in the sector.
The Path Forward: Consolidation and Maturation
Despite the dismal stock performance, the fundamental business of the top-tier MSOs has matured significantly. They are no longer the speculative, poorly managed entities of five years ago. Today, the survivors are focused on operational efficiency, debt reduction, and market dominance in their core states.
Operational Leanings
The current era for MSOs is one of discipline. Companies have curtailed aggressive expansion plans, closed underperforming retail locations, and optimized their cultivation yields to reduce costs. Many have begun to achieve genuine GAAP profitability, signaling a shift from a “growth at any cost” mentality to a “profitability as a necessity” approach. This maturity is often overlooked by a market scarred by past performance, but it provides a foundation that wasn’t present during the previous bull market.
Awaiting the Catalyst
The question of whether MSO stock will recover rests on a binary outcome: federal policy. The ongoing Department of Health and Human Services (HHS) recommendation to move cannabis from Schedule I to Schedule III would be the most significant turning point in the industry’s history. If reclassification occurs, the 280E tax burden would be eliminated, instantly transforming MSOs from high-tax, struggling entities into highly profitable businesses with strong cash flows.
However, the market is currently in a “wait and see” mode. Investors have been burned too many times to bet heavily on legislative promises without concrete results. The stocks remain depressed because the market is pricing in the worst-case scenario: a status quo that continues to strangle growth and siphon cash flow through taxation.
In conclusion, MSO stock performance is a case study in the risks of investing in a nascent industry trapped in regulatory limbo. The stocks fell because the initial thesis—rapid, unrestricted national growth—collided with the harsh reality of federal prohibition and high-interest debt. While the companies have become better operators, their financial potential is currently gated by government policy. Investors who hold MSO positions are essentially betting on the eventual alignment of state legal reality with federal law. Until that bridge is crossed, MSO stocks will likely continue to trade as high-risk, high-reward instruments, reflecting the deep uncertainty that still defines the American cannabis landscape.
aViewFromTheCave is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Amazon, the Amazon logo, AmazonSupply, and the AmazonSupply logo are trademarks of Amazon.com, Inc. or its affiliates. As an Amazon Associate we earn affiliate commissions from qualifying purchases.